MyMD Pharmaceuticals (DB:DQS0) - Hisse Senedi Fiyatı, Haberler ve Analizler

DQS0 Stoklara Genel Bakış

A clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms.

Şirket hakkında

DQS0 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 6.8% oranında arttı

Risk Analizi

Hisse senetleri oldukça likit değildir

1 yıldan az nakit akışı var

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( $0 )

+ 1 daha fazla risk

TNF Pharmaceuticals, Inc. Rakipler

Biofrontera

XTRA:B8FK

€17.5m

SynBiotic

DUSE:SBX

€29.9m

Cantourage Group

XTRA:HIGH

€56.1m

Redx Pharma

DB:0RX

€65.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti MyMD Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.89
52 Haftanın En Yüksek Seviyesi	US$61.80
52 Haftanın En Düşük Seviyesi	US$1.89
Beta	2.91
11 Aylık Değişim	0%
3 Aylık Değişim	-22.22%
1 Yıllık Değişim	-96.14%
33 Yıllık Değişim	-97.72%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-98.25%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	DQS0	DE Pharmaceuticals	DE Pazar
7D	0%	-0.8%	1.1%
1Y	-96.1%	-16.7%	12.5%

Getiri vs. Endüstri: DQS0 geçen yıl % -16.7 oranında getiri sağlayan German Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: DQS0 geçen yıl % 12.5 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is DQS0's price volatile compared to industry and market?
DQS0 volatility
DQS0 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.9%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: DQS0 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: DQS0 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	6	n/a	tnfpharma.com

TNF Pharmaceuticals, Inc. Temel Bilgiler Özeti

MyMD Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
DQS0 temel i̇stati̇sti̇kler
Piyasa değeri	€5.02m
Kazançlar(TTM)	-€7.62m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.7x

F/K Oranı

DQS0 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
DQS0 gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$8.22m
Kazançlar	-US$8.22m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.81
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

DQS0 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

DQS0 Stoklara Genel Bakış

Ödüller

Risk Analizi

TNF Pharmaceuticals, Inc. Rakipler

XTRA:B8FK

€17.5m

DUSE:SBX

€29.9m

XTRA:HIGH

€56.1m

DB:0RX

€65.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

TNF Pharmaceuticals, Inc., Annual General Meeting, Nov 25, 2024

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

TNF Pharmaceuticals, Inc. announced delayed 10-Q filing

MyMD Pharmaceuticals Announces Executive Appointments

MyMD Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc.

MyMD Pharmaceuticals, Inc. announced that it expects to receive $14 million in funding from PharmaCyte Biotech, Inc.

Recent updates

TNF Pharmaceuticals, Inc., Annual General Meeting, Nov 25, 2024

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

TNF Pharmaceuticals, Inc. announced delayed 10-Q filing

MyMD Pharmaceuticals Announces Executive Appointments

MyMD Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc.

MyMD Pharmaceuticals, Inc. announced that it expects to receive $14 million in funding from PharmaCyte Biotech, Inc.

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

New major risk - Market cap size

MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis

Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain

MyMD Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

MyMD Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023

Chief Legal Officer recently bought €154k worth of stock

FDA Accepts MyMD Pharmaceuticals, Inc. Investigational New Drug Application for Phase 2 Study of Oral Tnf-A Inhibitor Mymd-1®? in Rheumatoid Arthritis

Mymd Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral Tnf-A Inhibitor Mymd-1® in Sarcopenia/Age-Related Frailty

MyMD Pharmaceuticals, Inc., Annual General Meeting, Jul 31, 2023

MyMD Pharmaceuticals, Inc. to Present Data on Oral TNF-a Inhibitor MYMD-1 at the British Society for Immunology Congress 2022

MyMD Pharmaceuticals, Inc. Announces Publication of Phase 1 Data for Oral Tnf-Alpha Inhibitor Mymd-1® in Peer-Reviewed Journal Drug Research

MyMD Pharmaceuticals, Inc., Annual General Meeting, Dec 14, 2022

MyMD Pharmaceuticals, Inc. Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals, Inc. Announces the Publication of Data in the Journal of Gerontology Biological Sciences (JGBS) from A Pre-Clinical Study of MYMD-1

MyMD Pharmaceuticals, Inc. Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals, Inc.(NasdaqCM:MYMD) dropped from Russell Microcap Value Index

MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as A Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis

MyMD Pharmaceuticals, Inc Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals Inc Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals, Inc. Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

VP of Operations & General Counsel recently bought €80k worth of stock

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD

MyMD Pharmaceuticals, Inc. Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Independent Director Robert Schroeder has left the company

MyMD Pharmaceuticals, Inc. announced delayed 10-Q filing

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

TNF Pharmaceuticals, Inc. Temel Bilgiler Özeti

0.0x

-0.7x

Kazanç ve Gelir